CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY

marketwatch02-29

Please disregard the headline "Gilead Sciences Proposed to Acquire CymaBay for $32.50 Per Shr in Cash or a Total Equity Value of $4.3B," at 4:46 p.m. ET. The news was already reported Feb. 12.

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2415330305?lang=en_US&edition=fundamental","thumbnail":"https://images.barrons.com/im-10190352?size=1.777777777777778&width=220 220w","is_english":true,"pubTime":"2024-02-29 07:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2415330305","market":"us","top_or_hot":-1,"title":"CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY","media":"marketwatch","content":"<div>\n<p>Please disregard the headline \"Gilead Sciences Proposed to Acquire CymaBay for $32.50 Per Shr in Cash or a Total Equity Value of $4.3B,\" at 4:46 p.m. ET. The news was already reported Feb. 12.</p>\n\n<a href=\"https://www.marketwatch.com/story/cymabay-therapeutics-4q-loss-shr-35c-cbay-515eb2b6?mod=newsviewer_click\">Source Link</a>\n\n</div>\n","source":"mwatch_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCymaBay Therapeutics 4Q Loss/Shr 35c >CBAY\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-29 07:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/cymabay-therapeutics-4q-loss-shr-35c-cbay-515eb2b6?mod=newsviewer_click><strong>marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Please disregard the headline \"Gilead Sciences Proposed to Acquire CymaBay for $32.50 Per Shr in Cash or a Total Equity Value of $4.3B,\" at 4:46 p.m. ET. The news was already reported Feb. 12.</p>\n\n<a href=\"https://www.marketwatch.com/story/cymabay-therapeutics-4q-loss-shr-35c-cbay-515eb2b6?mod=newsviewer_click\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CBAY","symbol_name":"CymaBay Therapeutics Inc.","start_time":0,"source_url":"https://www.marketwatch.com/story/cymabay-therapeutics-4q-loss-shr-35c-cbay-515eb2b6?mod=newsviewer_click","article_id":"2415330305","we_media_id":null,"thumbnails":["https://images.barrons.com/im-10190352?size=1.777777777777778&width=220 220w"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2415330305","pubTimestamp":1709162700,"sourceInfo":{"source_id":"mwatch_stock","name":"Market Watch"},"weMediaInfo":null,"summary":"Please disregard the headline \"Gilead Sciences Proposed to Acquire CymaBay for $32.50 Per Shr in Cash or a Total Equity Value of $4.3B,\" at 4:46 p.m. ET. The news was already reported Feb. 12.","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CBAY":"CymaBay Therapeutics Inc.","BK4007":"制药"},"translate_title":"CymaBay Therapeutics 4Q损失/Shr 35c>CBAY","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CBAY":1},"content_text":"Please disregard the headline \"Gilead Sciences Proposed to Acquire CymaBay for $32.50 Per Shr in Cash or a Total Equity Value of $4.3B,\" at 4:46 p.m. ET. The news was already reported Feb. 12.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2415330305"}